TPG Affiliates Affirm Support for Rallybio's Merger with Candid Therapeutics

summarizeSummary

A major institutional investor, TPG, has formally committed its 7.2% stake to support Rallybio Corp's proposed reverse merger with Candid Therapeutics.

check_boxKey Events

• Major Shareholder Support

  TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, collectively hold 378,551 shares, representing 7.2% of Rallybio's common stock.

• Merger Support Agreement

  TPG's Rise Fund Rascal has entered into a Support Agreement, committing to vote all its shares in favor of the definitive merger agreement with Candid Therapeutics, Inc., which was announced on March 2, 2026.

• Strategic Alignment

  The agreement also stipulates that TPG will vote against any proposals opposing the merger and will not solicit alternative acquisition proposals, reinforcing the strategic direction.

auto_awesomeAnalysis

This Schedule 13D/A confirms that TPG GP A, LLC and its principals, holding a significant 7.2% stake in Rallybio Corp, have entered into a Support Agreement to vote in favor of the recently announced reverse merger with Candid Therapeutics, Inc. This public commitment from a major institutional investor strengthens the likelihood of the merger's successful completion, providing crucial backing for the company's strategic transformation, following the definitive merger agreement announced on March 2, 2026.